GB Sciences, Inc. GBLX

GBLX Company Overview

GB Sciences, Inc. is a biotechnology company focused on the research and development of cannabinoid-based medicines. The company operates primarily in the pharmaceutical research and life sciences industry, with an emphasis on developing therapeutic products derived from cannabis and other plant-based compounds. Its business model centers on early-stage drug discovery, preclinical research, and intellectual property development rather than commercial-scale product sales.

The company’s core focus has been on cannabinoid formulations targeting neurological and metabolic disorders, including conditions such as Parkinson’s disease and other central nervous system indications. GB Sciences positions itself as a science-driven organization seeking to differentiate through patented formulations, proprietary delivery methods, and a research-oriented approach rather than recreational cannabis production. The company was founded in 2014 and evolved from a broader life sciences focus into a cannabinoid-centric research platform as regulatory frameworks for medical cannabis expanded in the United States.